Compare BioNTech SE - ADR (BNTX) vs Southwest Airlines Co (LUV) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
BioNTech SE - ADR vs Southwest Airlines Co — how do they compare? BioNTech SE - ADR trades at $93.1 (market cap $23.31B), while Southwest Airlines Co trades at $44.85 (market cap $22.27B). The key difference: BioNTech SE - ADR and Southwest Airlines Co are close in size by market cap, and Southwest Airlines Co pays a 1.58% dividend while BioNTech SE - ADR pays none. Which is the better fit depends on your goals.
| BNTX | LUV | |
|---|---|---|
Market Cap | $23.31B | $22.27B |
Sector | Health | Industrials |
52-Week High | $119.34 | $54.80 |
52-Week Low | $83.89 | $29.67 |
Enterprise Value | $6.60B | $25.37B |
Dividend Yield | — | 1.58% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BioNTech (BNTX) trades at $92.80, down 0.93% on the day, reflecting ongoing pressure from declining COVID-19 vaccine revenue. The stock shows a bullish technical signal from moving averages but faces fundamental headwinds with a net loss of $1.14 billion in 2025 and negative profit margins. Recent Q2 2026 earnings missed expectations, and the company lowered its full-year sales outlook due to soft vaccine demand. Analyst consensus remains strongly bullish with a $121 price target, betting on the long-term potential of its oncology pipeline.
The investment case hinges on BioNTech's transition from COVID-19 vaccines to its deep oncology pipeline, valued near zero given its cash-rich balance sheet. Near-term risks include persistent earnings losses and volatile vaccine revenue, but the company's strong liquidity position and 14 pivotal clinical trials offer substantial upside if pipeline successes materialize. Investors are essentially getting the oncology assets for free, but execution risk is high.
Southwest Airlines (LUV) trades at $44.9, down 4.57% on the day, with a bearish technical signal from moving averages. The company reported mixed quarterly earnings, beating in Q2 2026 but missing in Q1 2026, while revenue growth is projected to rise to $30.1B in 2026. Recent news highlights board appointments and initiatives to attract business travelers, amid a volatile fuel cost environment.
LUV presents a cautious opportunity with a consensus price target of $53.86 implying upside, supported by improving cash flow and dividend payments. Risks include fuel price volatility, execution on new business offerings, and competitive pressures, requiring careful monitoring of earnings consistency and cost management.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About BioNTech SE - ADR
BioNTech is a Germany-based biotechnology company that focuses on developing cancer therapeutics, including individualized immunotherapy, as well as vaccines for infectious diseases, including COVID-19. The company's oncology pipeline contains several classes of drugs, including mRNA-based drugs to encode antigens, neoantigens, cytokines, and antibodies.
Read more on BNTX →About Southwest Airlines Co
Southwest Airlines is the largest domestic carrier in the United States, as measured by the number of originating passengers boarded. Southwest operates over 700 aircraft in an all-Boeing 737 fleet. Despite expanding into longer routes and business travel, the airline still specializes in short-haul leisure flights, using a point-to-point network. Southwest operates a low-cost carrier business model.
Read more on LUV →
